Monitoring Principles for Metastatic Breast Cancer

To ensure accuracy, imaging must be performed using serial and regular repetition of the same types of studies. The most reliable way to track changes is to compare new scans directly against previously abnormal studies. This allows the clinician to distinguish between stable disease, partial response, and true progression.

The Challenge of Bone-Dominant Disease

In patients where the cancer is primarily located in the bones, monitoring becomes more complex. Assessing changes in bone lesions can be difficult using standard plain films, cross-sectional radiology, or even bone scans. In these specific clinical scenarios, imaging alone may not be sufficient to capture the nuances of the disease. Instead, clinicians should rely more heavily on patient symptoms and serum tumor markers to provide necessary clinical guidance.

Blood Biomarkers and Tumor Markers

Serum tumor markers are biochemical indicators that can reflect disease activity. In breast cancer management, the most commonly utilized markers include:

• Carcinoembryonic antigen (CEA)
• CA 15-3
• CA 27.29

While these markers are valuable, they must be interpreted with significant caution. A rising trend in these markers may suggest tumor progression, but it is not a definitive rule; markers can occasionally rise even during periods where the disease is responding to treatment.

Exam Warning: An isolated increase in tumor markers should rarely be used as the sole basis for declaring disease progression. Clinical and radiographic confirmation is typically required to avoid premature changes in therapy.

Objective Criteria for Response and Stability

The ultimate goal of monitoring is to categorize the patient's response into objective criteria, such as response, stability, or progression.

The frequency of these assessments is not fixed; it is dynamic and tailored to the individual. For example, if a patient achieves long-term stable disease, the frequency of clinical monitoring may be safely reduced to minimize patient burden. Conversely, if a patient shows signs of instability, monitoring must intensify.

By integrating these various streams of data—symptoms, imaging, and biomarkers—clinicians can optimize the therapeutic window, ensuring the patient stays on effective treatments while minimizing exposure to the toxicities of drugs that are no longer working.